XENE
Xenon Pharmaceuticals Inc.
Overview
Xenon Pharmaceuticals develops small-molecule drugs targeting ion channels to treat neurological and psychiatric disorders. The company's lead candidate, azetukalner, is in Phase 3 trials for epilepsy and depression, while earlier-stage programs target pain and other conditions through potassium and sodium channel modulation.
Xenon Pharmaceuticals Inc is a Healthcare company operating in Biotechnology with a $5.11B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 9, 2026).
20 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0713 Q&A exchanges
- Q3 FY2025Earnings2025-11-0412 Q&A exchanges
- Q2 FY2025Earnings2025-08-1113 Q&A exchanges
- Q1 FY2025Earnings2025-05-1211 Q&A exchanges
- Q4 FY2024Earnings2025-02-2717 Q&A exchanges
- Q3 FY2024Earnings2024-11-1215 Q&A exchanges
- Q2 FY2024Earnings2024-08-0922 Q&A exchanges
- Q1 FY2024Earnings2024-05-0915 Q&A exchanges
- Q4 FY2023Earnings2024-02-2923 Q&A exchanges
- Q3 FY2023Earnings2023-11-0812 Q&A exchanges
- Q2 FY2023Earnings2023-08-0916 Q&A exchanges
- Q1 FY2023Earnings2023-05-1320 Q&A exchanges
- Q4 FY2022Earnings2023-03-0130 Q&A exchanges
- Q3 FY2022Earnings2022-11-0811 Q&A exchanges
- Q2 FY2022Earnings2022-08-1023 Q&A exchanges
- Q1 FY2022Earnings2022-05-1016 Q&A exchanges
- Q4 FY2021Earnings2022-03-0119 Q&A exchanges
- Q3 FY2021Earnings2021-11-1021 Q&A exchanges
- Q2 FY2021Earnings2021-08-1123 Q&A exchanges
- Q1 FY2021Earnings2021-05-1126 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-09EPS— vs $-1.16—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-09 | — | $-1.16 | — | — | — | — | EODHD |
Source: EODHD. XENE reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks XENE's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 90% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $0.95 | $0.83 | +14.9% | +0.6% | -0.9% |
| Q4 FY2026 | $0.73 | $0.65 | +12.7% | +2.0% | +3.7% |
| Q3 FY2026 | $0.76 | $0.64 | +18.0% | -0.1% | -1.8% |
| Q2 FY2026 | $0.69 | $0.63 | +10.1% | +8.0% | +6.4% |
| Q1 FY2025 | $1.10 | $0.89 | +23.9% | +7.8% | +6.9% |
| Q4 FY2025 | $0.87 | $0.80 | +9.2% | +6.0% | +3.5% |
| Q3 FY2025 | $0.80 | $0.71 | +12.0% | +1.8% | -0.1% |
| Q2 FY2025 | $1.24 | $1.00 | +23.9% | +0.4% | +0.9% |
| Q1 FY2024 | $0.91 | $0.83 | +10.0% | +5.5% | +6.3% |
| Q4 FY2024 | $0.88 | $0.79 | +11.4% | +7.8% | +5.7% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Ian MortimerCEO8 mo20 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • guidance suspended Q3 FY2026
- Thomas Patrick KellyCFO8 mono recorded callsCurrentSample
CFO since 2025 • 2/4 beats (50%) • last call held guidance Q2 FY2026
- Darren S ClineChief Commercial Officer1 yr3 callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • last guidance cut Q2 FY2026
- Christopher John KenneyChief Medical Officer1 yr 3 mo2 callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last call held guidance Q2 FY2026
- Andrea DifabioChief Legal Officer1 yr 3 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • guidance suspended Q2 FY2026
- Sherry AulinCFO0 mo17 callsFormerSample
CFO since 2024 • 6/8 beats (75%) • last guidance raise Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for XENE.
$ curl https://api.spokenalpha.com/v1/companies/XENEFAQ
Frequently asked about XENE
Where can I find Xenon Pharmaceuticals Inc.'s (XENE) earnings call transcripts?
Spoken Alpha indexes XENE's earnings call transcripts at https://spokenalpha.com/companies/XENE. Each call links to attributed speakers and parsed analyst Q&A.
When was Xenon Pharmaceuticals Inc.'s most recent earnings call?
Xenon Pharmaceuticals Inc. (XENE) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
What sector is XENE in?
Xenon Pharmaceuticals Inc. (XENE) operates in the Healthcare sector (Biotechnology industry).